Q5127 Pegflilgrastim-fpgk - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Pegflilgrastim-fpgk

Brand Name:

Stimufend

Strength:

0.5mg

HCPCS:

Q5127

SEER*Rx Category:

Ancillary Therapy

Major Drug Class:

Immunostimulant

Minor Drug Class:

Granulocyte colony stimulating factor

Oral (Y/N):

No

FDA Approval Year:

2022

FDA Discontinuation Year:

CMS Effective Date:

March 17, 2023

CMS Discontinuation Date:

Status:

In Use